CA3235911A1 - Stable ready to dilute composition of carfilzomib - Google Patents

Stable ready to dilute composition of carfilzomib Download PDF

Info

Publication number
CA3235911A1
CA3235911A1 CA3235911A CA3235911A CA3235911A1 CA 3235911 A1 CA3235911 A1 CA 3235911A1 CA 3235911 A CA3235911 A CA 3235911A CA 3235911 A CA3235911 A CA 3235911A CA 3235911 A1 CA3235911 A1 CA 3235911A1
Authority
CA
Canada
Prior art keywords
component
carfilzomib
pharmaceutically acceptable
acceptable salts
dilute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235911A
Other languages
English (en)
French (fr)
Inventor
Paras Rasiklal VASANANI
Sandip Pareshbhai MEHTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kashiv Biosciences LLC
Original Assignee
Kashiv Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashiv Biosciences LLC filed Critical Kashiv Biosciences LLC
Publication of CA3235911A1 publication Critical patent/CA3235911A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3235911A 2021-10-21 2022-10-21 Stable ready to dilute composition of carfilzomib Pending CA3235911A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121047991 2021-10-21
IN202121047991 2021-10-21
PCT/IB2022/060145 WO2023067569A1 (en) 2021-10-21 2022-10-21 Stable ready to dilute composition of carfilzomib

Publications (1)

Publication Number Publication Date
CA3235911A1 true CA3235911A1 (en) 2023-04-27

Family

ID=86058874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235911A Pending CA3235911A1 (en) 2021-10-21 2022-10-21 Stable ready to dilute composition of carfilzomib

Country Status (7)

Country Link
US (2) US12440534B2 (https=)
EP (1) EP4419080A4 (https=)
JP (1) JP2024537910A (https=)
CN (1) CN118434408A (https=)
AU (1) AU2022369145A1 (https=)
CA (1) CA3235911A1 (https=)
WO (1) WO2023067569A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016185450A1 (en) * 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
WO2018047074A1 (en) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10098890B2 (en) * 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138557A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Ready-to-use carfilzomib compositions
US20260048003A1 (en) * 2020-01-10 2026-02-19 Amgen Inc. Stable cyclodextrin free carfilzomib formulation
CA3180338A1 (en) * 2020-04-15 2021-10-21 Kashiv Biosciences, Llc Stable ready to dilute formulations of carfilzomib

Also Published As

Publication number Publication date
US20240269224A1 (en) 2024-08-15
WO2023067569A1 (en) 2023-04-27
EP4419080A1 (en) 2024-08-28
CN118434408A (zh) 2024-08-02
AU2022369145A1 (en) 2024-05-23
US20260014226A1 (en) 2026-01-15
JP2024537910A (ja) 2024-10-16
EP4419080A4 (en) 2025-12-24
US12440534B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
US10493079B2 (en) Stable carfilzomib formulations
US20110152360A1 (en) Liquid pharmaceutical formulations of docetaxel
EA027869B1 (ru) Стабилизированная композиция такролимуса
US10512654B2 (en) Pharmaceutical composition including dutasteride and capsule formulation comprising the same
US20230158099A1 (en) Stable ready to dilute formulations of carfilzomib
US12440534B2 (en) Stable ready to dilute composition of carfilzomib
CA2625862A1 (en) Liquid pharmaceutical compositions of nimodipine
US20100210681A1 (en) Aqueous pharmaceutical composition
BR112019016545A2 (pt) Composição para administração intravesical para tratamento de dor na bexiga
US20090048346A1 (en) Therapeutic formulations
US20160120742A1 (en) Compositions including cabazitaxel
WO2026003874A1 (en) Injectable compositions of apixaban
WO2024224424A1 (en) Injectable compositions of metolazone
WO2024127418A1 (en) Injectable compositions of posaconazole
AU2006257718A1 (en) Liquid pharmaceutical formulations of docetaxel

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240417

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250326

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250722

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250828

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828